Purchases of medical therapy recommended for coronary artery disease before and after elective revascularisation.
Jari HeiskanenJuha HartikainenJanne MartikainenHeikki MiettinenMikko HippeläinenRisto P RoineAnna-Maija TolppanenPublished in: European journal of clinical pharmacology (2019)
In both PCI and CABG patients, the use of medical therapy before and after revascularisation procedure complied with current guidelines. Purchases of long-acting nitrates were common in the PCI group even after the procedure.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- coronary artery bypass grafting
- end stage renal disease
- healthcare
- acute coronary syndrome
- acute myocardial infarction
- newly diagnosed
- minimally invasive
- chronic kidney disease
- peritoneal dialysis
- atrial fibrillation
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- cardiovascular events
- prognostic factors
- patients undergoing
- heart failure
- stem cells
- patient reported outcomes
- clinical practice
- aortic valve